Six studies examined TROP-2 expression in patients with colorectal cancer, two studies included patients who had undergone surgery for gastric carcinoma, one study evaluated TROP-2 expression in patients with pancreatic cancer and one study analyzed tissue specimens from gallbladder carcinomas. Here, TACSTD2 is linked to colorectal cancer.